Related Experiment Videos
Hydralazine pharmacodynamics in the dog
American Journal of Veterinary Research
|August 1, 1983
Summary
Hydralazine significantly improved cardiac performance in dogs with heart failure by increasing cardiac output and stroke volume. The arteriolar dilator demonstrated a notable effect on hemodynamics, though some adverse events were observed.
Area of Science:
- Cardiovascular Pharmacology
- Heart Failure Pathophysiology
- Drug Pharmacodynamics
Background:
- Heart failure is a complex condition characterized by impaired cardiac function.
- Arteriolar dilators are used to manage cardiovascular diseases.
- Understanding drug effects in heart failure models is crucial for therapeutic development.
Purpose of the Study:
- To investigate the pharmacodynamics of hydralazine in a canine model of induced heart failure.
- To assess the hemodynamic effects of hydralazine on cardiac output, systemic resistance, and pressures.
- To determine the onset, peak, and duration of hydralazine's therapeutic action.
Main Methods:
- Heart failure was induced in dogs using microsphere injection.
- Hydralazine was administered orally at a dose of 1 mg/kg hourly until systemic resistance decreased.
- Hemodynamic parameters were continuously monitored to assess drug efficacy and duration.
Main Results:
- Hydralazine increased cardiac index (3.06 to 6.81 L/min/m2) and stroke volume index (20.9 to 36.8 ml/beat/m2).
- Total systemic resistance index significantly decreased (2,903 to 992 dynes.s.cm-5.m2).
- Mean arterial pressure decreased, while heart rate increased; left ventricular filling pressure and contractility remained unaffected.
Conclusions:
- Hydralazine effectively improved cardiac performance in dogs with induced left ventricular failure.
- The drug's peak effect was observed 3-5 hours post-administration, with a duration of 11-13 hours.
- While beneficial, potential adverse events like ventricular dysrhythmias warrant consideration.